• 无工作经验
  • 博士
  • 招1人
  • 01-26 发布
  • 五险一金
  • 通讯补贴

职位描述

Overview:CStone is seeking a Scientist with expertise in drug metabolism and pharmacokinetics (DMPK) to be based in Shanghai, China. This scientist will represent the Drug Disposition component as an ADME Project Leader, with responsibility for guiding DMPK related activities on early drug discovery teams.Responsibilities:?Design and implement aggressive, innovative preclinical ADME plans for drug discovery projects?As a subject matter expert, work with Drug Disposition colleagues, project teams, and external experts to develop a strategy for identifying and solving issues in your area of expertise?Responsible for the review and preparation of DMPK documents for IND submission?Integrate in vitro, in vivo, and in silico ADME data with discovery biology and medicinal chemistry to define structure activity relationships to drug design strategies and help optimize drug properties?Interact across groups, including other departments, regulatory agencies, and functional groups within drug disposition?Responsible for the design, oversight, interpretation, and reporting of preclinical study results.?Design/execution of preclinical PK/PD studies?Lead internal and collaborative research to increase mechanistic understanding of clearance pathways and/or drug distribution and improve translatability of preclinical modelsPrepare preclinical data packages and regulatory submissions to enable clinical studies.Education/Qualification:?Ph.D. degree in Pharmacokinetics or an advanced degree in a related science with extensive training in the field of drug metabolism and disposition.?At least 4 years of direct experience in drug discovery.Excellent verbal and written communication skills, with fluency in English.Desirable skills:?Strong interpersonal and team-building skills, including demonstrated experience working in a team environment?Experience in managing external contract research organizations (CRO)?Medicinal chemistry expertise is highly desirable?Regulatory experience in Pharm/Toxicology is highly preferred?Proficiency with PBPK software (e.g. SimCYP or Gastroplus), and WinNolin. 职能类别: 生物工程/生物制药

联系方式

张衡路1000弄25号楼

公司信息

CStone Pharmaceuticals is an innovative, research-based, biopharmaceutical company committed to the development of a new generation of therapeutic drugs. Based in both Shanghai and Suzhou, the company's leadership team consists of seasoned executives from top pharmaceutical MNCs. In July 2016, CStone announced the completion of its Series A financing, raising a total of US$150 million (about 975 million RMB). Three prestigious investment companies in the industry, Oriza Seed Venture Capital (Oriza Seed), Boyu Capital, and WuXi Healthcare Ventures (WXHV), jointly invested in the round. With an overarching commitment to meeting the most pressing needs of Chinese patients, the company's pipeline covers five therapeutic areas, including oncology, cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases. With immuno-oncology as CStone's core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy.基石药业是一家创新的研发驱动型生物制药公司,致力于开发新一代的治疗性药物,创立于中国上海和苏州两地,公司的领导团队由来自国际顶尖药企的管理层成员组成。 2016年7月宣布完成A轮融资,共募集到1.5亿美元(约9.75亿人民币)资金,由三家颇具声望的投资公司参与,分别是元禾原点创业投资管理有限公司、博裕资本及毓承资本。目前,基石药业拥有肿瘤、心血管、风湿性关节炎、血液病及自身免疫病等五个治疗领域的产品线,旨在满足中国病患重大迫切的临床需求。在广受瞩目的肿瘤治疗领域,基石药业以其出色的肿瘤免疫药物为核心,凭借其世界级的研发团队,最前沿的药物研发项目,以及开放式创新的策略有望引领国内新药研发行业走向全球。

猎才二维码